---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-026766"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:38:12.665817+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Puma announces acceptance of alisertib + pembrolizumab poster at AACR-NCI-EORTC conference

## Summary
- Investigator-sponsored Phase I/II trial of alisertib plus pembrolizumab accepted for poster presentation.
- Trial targets Rb-deficient head and neck squamous cell carcinoma (HNSCC).
- Poster presentation at late-breaking session C on Oct 14, 2023, 12:30-4:00 pm ET, as LB_C12.
- Conference: 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
- No clinical data results announced; this is a trial update.

## SEC filing metadata
- accession: 0001437749-23-026766
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774923026766/0001437749-23-026766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774923026766/pbyi20230925_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-026766
- JSON: https://secwatch.observer/filing/0001437749-23-026766.json
- Plain text: https://secwatch.observer/filing/0001437749-23-026766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.